![]() |
![]() |
![]() |
![]() |
![]() |
![]() |


Krishna Saxena joined the SGC Frankfurt July 2020. Krishna studied Biochemistry in Frankfurt (Germany) followed by a PhD (1999) in heterologous expression of membrane proteins at the Institute of Biochemistry (Frankfurt). Then, he was leading a molecular biology and protein expression group for a collaboration between Aventis Research & Technologies and the Goethe University (1999-2001), later MRPharm (2001-2002), a biotechnology company spin out of Frankfurt University and shortly part of Affinium Pharmaceuticals. The focus of his work became structure-based drug discovery by NMR spectroscopy and X-ray diffraction. From 2003-2011, he was working as a group leader (collaboration Sanofi and Goethe University) to study the family of protein kinases and subsequently to investigate biomedically relevant protein-protein interactions (PPIs) with focus on the modulation of such interactions by low molecular weight ligands guided by NMR technology. Since 2012, he has worked in the drug development platform at the DKTK German Cancer Consortium and for several industrial collaborations.
Front Mol Biosci. 2021 8:653148. doi: 10.3389/fmolb.2021.653148
PMID: 34041264
ChemMedChem. 2018 13(16):1629-1633. doi: 10.1002/cmdc.201800398
PMID: 29928781
2023
Cell Chem Biol. 20.06.2023 . doi: 10.1016/j.chembiol.2023.06.002
PMID: 37354907
Biomol NMR Assign. 29.04.2023 . doi: 10.1007/s12104-023-10132-8
PMID: 37118562
2022
Front Cell Dev Biol. 21.06.2022 10:886537. doi: 10.3389/fcell.2022.886537
PMID: 35721509
2021
Front Mol Biosci. 28.05.2021 8:653148. doi: 10.3389/fmolb.2021.653148
PMID: 34041264
2018
ChemMedChem. 20.08.2018 13(16):1629-1633. doi: 10.1002/cmdc.201800398
PMID: 29928781